Diabetic retinopathy or DR is a vision-threatening micro-vascular complication of diabetes that occurs in virtually all patients with type-1 diabetes (T1D).Proliferative diabetic retinopathy (PDR) is a very advanced-stage of diabetic retinopathy. At this phase, circulation problems rob the retina of oxygen. This allows the new blood-vessels to grow in the retina & vitreous-humor, the jelly-like liquid that fills the back of the eye. The new blood-vessels may leak the blood into vitreous and clouding vision. One of the main symptoms of PDR is progressive vision loss, especially in patients who are not receiving adequate monitoring or treatment. Apart from this, major risk factor for PDR includes duration of diabetes, since 30-34 years of diabetes increases the risk of retinopathy. Therefore, the increasing prevalence of diabetes directly contributes to a further increase in the prevalence of PDR.
PDR is generally illustrates by retinal-neovascularization, serum-loss, hemorrhage, and fibrovascular proliferation at the retinal vitreous interface. This further leads to the vitreous hemorrhage and replacement of the retina. Therefore, if left untreated, PDR can lead to severe vision loss. Laser photocoagulation has been one of the main treatment methods for ROP in recent years. Hence, as the number of people living with diabetes increases, it is expected to help the market growth in the region.
As per analysis, Global Proliferative Diabetic Retinopathy Therapeutics Industry Research Report 2021 Segmented by Major Market Players, Types, Applications and Countries Forecast to 2027. Some of the key companies operating in the global proliferative diabetic retinopathy therapeutics market include Aerie Pharmaceuticals Inc., Ohr Pharmaceutical Inc, Ribomic Inc, Acucela Inc, ThromboGenics NV, Antisense Therapeutics Ltd, PanOptica Inc, Icon Bioscience Inc and among others. The global proliferative diabetic retinopathy therapeutics market is moderately fragmented with the presence of different small & widespread companies. This market is generally characterized by intense competition among participants within the international & regional industry fronts.
Based on types, proliferative diabetic retinopathy therapeutics market has been segmented as Squalamine Lactate, PAN-90806, THR-687, RBM-008, Ocriplasmin and others. In addition, based on application, market has been segmented as home-care, clinic and hospitals.
Request For Sample Report-https://kenresearch.com/sample-report.php?Frmdetails=NDQ0NTQy
Increase in incidence of blindness due to diabetes, followed by rise in awareness for treatment of diabetic retinopathy, growth in geriatric population and rise in prevalence of diabetes are some major factors, which are responsible for growth of the proliferative diabetic retinopathy therapeutics market. Apart from this, dearth of skilled ophthalmologists and extended approval time for drugs may impact the market. Moreover, emergence of combined therapies is a leading opportunity for market.
Based on regional analysis, the North-America is a leading region in global proliferative diabetic retinopathy therapeutics market owing to increase in use of anti-VEGF drugs and presence of state-of-the-art healthcare infrastructure across the region. The Asia-Pacific and Europe regions are anticipated to witness higher growth rate due to increase in patient awareness over the forecast period. It is estimated that future of the global proliferative diabetic retinopathy therapeutics market will be optimistic on account of rise in prevalence of diabetes during the forecast period.
For More Information, refer to below link:-
Global Proliferative Diabetic Retinopathy Therapeutics Market Research Report
Related Post-
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
support@kenresearch.com
+91-9015378249
Follow Us-
LinkedIn | Instagram | Facebook | Twitter | YouTube
